Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies

Nature Medicine

Volumn 6, Issue 2, 2000, Pages 207-210

  Mascola, John R ^a,b   Stiegler, Gabriela ^c   Vancott, Thomas C ^a   Katinger, Hermann ^c   Carpenter, Calvin B ^d   Hanson, Chris E ^d   Beary, Holly ^a   Hayes, Deborah ^a   Frankel, Sarah S ^a   Birx, Deborah L ^a   Lewis, Mark G ^a  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPROPHYLAXIS; LYMPHOCYTE DEPLETION; MACACA; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIREMIA; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, MONOCLONAL; CHIMERA; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNITY, MUCOSAL; IMMUNIZATION, PASSIVE; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0033951746     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/72318     Document Type: Article

References (22)

1. Reimann, K.A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-Like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922-6928 (1996).
2. Reimann, K.A. et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian human immunodeficiency virus in rhesus monkeys. J. Virol. 70, 3198-3206 (1996).
3. Shibata, R. et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176, 362-373 (1997).
4. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med. 5, 204-210 (1999).
5. Mascola, J.R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
6. Piot, P. The science of AIDS: A tale of two worlds. Science 280, 1844-1845 (1998).
7. Miller, C.J. & McGhee, J.R. Progress towards a vaccine to prevent sexual transmission of HIV. Nature Med. 2, 751-752 (1996).
8. Spira, A.I. et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183, 215-225 (1996).
9. Frankel, S.S. et al. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 272, 115-117 (1996).
10. Marx, P.A. et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nature Med. 2, 1084-1089 (1996).
11. Burton, D.R. & Montefiori, D.C. The antibody response in HIV-1 infection. AIDS 11 Suppl. A, 587-598 (1997).
12. Lambert, J.S. et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. J. Infect. Dis. 175, 283-291 (1997).
13. Mascola, J.R. et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71, 7198-7206 (1997).
14. Lu, Y.C., Pauza, C.D., Lu, X.S., Montefiori, D.C., & Miller, C.J. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J. Acquir.Immune Defic. Syndr. Hum. Retrovirol. 19, 6-18 (1998).
15. Frankel, S.S. et al. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J. Virol. 72, 9788-9794 (1998).
16. Kutteh, W.H., Moldoveanu, Z., & Mestecky, J. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res. Hum. Retroviruses 14 (Suppl. 1), 51-55 (1998).
17. + cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J. Pediatr. 130, 890-897 (1997).
18. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
19. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
20. Lewis, M.G. et al. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J. Virol. 73, 1262-1270 (1999).
21. Vahey, M.T. & Wong, M.T. in PCR Primer. A Laboratory Manual 313-338. (Cold Spring Harbor Press, Plainview, NY, 1995).
22. Artenstein, A.W. et al. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J. Infect. Dis. 175, 265-271 (1997).